Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04491734 · ClinicalTrials.gov registry record · NA
Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease
A NA study of Gastroesophageal Reflux, sponsored by ISOThrive.
- Completed
- Registry status
- NA
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT04491734 is a NA study of Gastroesophageal Reflux that has completed, run by ISOThrive. The registered enrollment target is 156 participants, below the 179-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04491734, a NA study of Gastroesophageal Reflux, has completed, sponsored by ISOThrive.
- COMPLETED
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a remote study. No office visits required. The purpose and efficacy endpoint of this study is to assess whether GERD patients tolerate ISOT-101. In addition, usage of the ReQuest validated questionnaire to measure GERD symptoms will be explored as well as usage of the validated SF-36 quality of life (QoL) questionnaire. Each subject serves as his/her own control. Relative tolerability in subjects both on and off proton pump inhibitors (PPIs) will be compared. Subjects naive to PPIs, currently taking PPIs and historically on PPIs will be evaluated with ReQuest and QoL scores. In addition, survey measurements will be taken on a subset of 10 subjects that are non-responders to PPIs. These will not be included in the statistical analysis with the above groups. A tertiary endpoint of this study is to assess any relevant adverse events that occur.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT maltosyl-isomalto-oligosaccharides (MIMO)
Study Locations (1)
Virginia
- ISOThrive Inc. - Manassas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-08-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04491734
The ClinicalTrials.gov registry entry for NCT04491734 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (13% lower). The listed sponsor is ISOThrive, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which maltosyl-isomalto-oligosaccharides (MIMO) is the first listed.
NCT04491734 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04491734 about?
NCT04491734 is a clinical study titled "Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease". This is a remote study. No office visits required. The purpose and efficacy endpoint of this study is to assess whether GERD patients tolerate ISOT-101. In addition, usage of the ReQuest validated questionnaire to measure GERD symptoms will be explored as well as usage of the validated SF-36 quality...
What is the current status of trial NCT04491734?
This trial is currently completed. It is a NA study. The enrollment target is 156 participants. The study started on 2020-06-01. Estimated completion is 2021-08-26.
What conditions does trial NCT04491734 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux.
What interventions are being tested in trial NCT04491734?
The interventions under investigation include: maltosyl-isomalto-oligosaccharides (MIMO) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04491734?
This trial is sponsored by ISOThrive, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04491734 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.